Skylands Capital’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $453K | Sell |
60,570
-24,805
| -29% | -$262K | 0.06% | 125 |
|
|
2026
Q1 | $967K | Sell |
85,375
-7,351
| -8% | -$100K | 0.13% | 107 |
|
|
2025
Q4 | $1.19M | Sell |
92,726
-13,637
| -13% | -$210K | 0.16% | 94 |
|
|
2025
Q3 | $1.99M | Sell |
106,363
-24,473
| -19% | -$482K | 0.27% | 78 |
|
|
2025
Q2 | $3.35M | Sell |
130,836
-19,299
| -13% | -$388K | 0.49% | 57 |
|
|
2025
Q1 | $3M | Buy |
150,135
+11,054
| +8% | +$233K | 0.43% | 62 |
|
|
2024
Q4 | $2.53M | Buy |
139,081
+1,310
| +1% | +$25.7K | 0.35% | 69 |
|
|
2024
Q3 | $4.13M | Sell |
137,771
-4,268
| -3% | -$93.6K | 0.56% | 54 |
|
|
2024
Q2 | $2M | Sell |
142,039
-1,739
| -1% | -$30.2K | 0.28% | 79 |
|
|
2024
Q1 | $2.73M | Sell |
143,778
-18,933
| -12% | -$369K | 0.38% | 68 |
|
|
2023
Q4 | $3.61M | Buy |
162,711
+15,477
| +11% | +$460K | 0.53% | 53 |
|
|
2023
Q3 | $5.54M | Buy |
147,234
+7,560
| +5% | +$434K | 0.84% | 34 |
|
|
2023
Q2 | $10M | Buy |
139,674
+1,925
| +1% | +$122K | 1.44% | 16 |
|
|
2023
Q1 | $9.28M | Buy |
137,749
+10,644
| +8% | +$639K | 1.36% | 19 |
|
|
2022
Q4 | $3.94M | Buy |
127,105
+9,753
| +8% | +$289K | 0.62% | 42 |
|
|
2022
Q3 | $3.19M | Buy |
117,352
+1,102
| +0.9% | +$43K | 0.52% | 45 |
|
|
2022
Q2 | $5.09M | Buy |
116,250
+9,852
| +9% | +$452K | 0.75% | 36 |
|
|
2022
Q1 | $6.79M | Buy |
106,398
+9,079
| +9% | +$650K | 0.82% | 35 |
|
|
2021
Q4 | $8.16M | Buy |
97,319
+5,442
| +6% | +$611K | 0.94% | 32 |
|
|
2021
Q3 | $14.9M | Buy |
91,877
+3,277
| +4% | +$532K | 1.84% | 11 |
|
|
2021
Q2 | $13.4M | Buy |
88,600
+9,740
| +12% | +$1.64M | 1.58% | 16 |
|
|
2021
Q1 | $13.7M | Buy |
78,860
+2,490
| +3% | +$475K | 1.74% | 14 |
|
|
2020
Q4 | $12.2M | Buy |
76,370
+5,285
| +7% | +$885K | 1.77% | 17 |
|
|
2020
Q3 | $11.3M | Buy |
71,085
+11,445
| +19% | +$2.07M | 1.89% | 13 |
|
|
2020
Q2 | $11.8M | Buy |
59,640
+3,325
| +6% | +$611K | 2.09% | 10 |
|
|
2020
Q1 | $8.71M | Buy |
56,315
+15,522
| +38% | +$1.57M | 1.93% | 12 |
|
|
2019
Q4 | $3.14M | Buy |
40,793
+2,080
| +5% | +$181K | 0.46% | 52 |
|
|
2019
Q3 | $3.89M | Buy |
38,713
+4,683
| +14% | +$545K | 0.57% | 47 |
|
|
2019
Q2 | $4.5M | Buy |
34,030
+2,227
| +7% | +$306K | 0.62% | 45 |
|
|
2019
Q1 | $4.82M | Buy |
31,803
+7,010
| +28% | +$1.09M | 0.67% | 37 |
|
|
2018
Q4 | $4.01M | Buy |
24,793
+1,890
| +8% | +$375K | 0.66% | 38 |
|
|
2018
Q3 | $5.91M | Sell |
22,903
-1,925
| -8% | -$483K | 0.76% | 30 |
|
|
2018
Q2 | $5.66M | Sell |
24,828
-9,520
| -28% | -$1.8M | 0.75% | 32 |
|
|
2018
Q1 | $4.84M | Sell |
34,348
-1,932
| -5% | -$292K | 0.64% | 39 |
|
|
2017
Q4 | $4.72M | Buy |
36,280
+11,277
| +45% | +$1.43M | 0.61% | 43 |
|
|
2017
Q3 | $3.1M | Sell |
25,003
-4,710
| -16% | -$480K | 0.41% | 58 |
|
|
2017
Q2 | $2.56M | Buy |
29,713
+13,883
| +88% | +$1.22M | 0.35% | 70 |
|
|
2017
Q1 | $1.42M | Buy |
15,830
+14,680
| +1,277% | +$1.64M | 0.2% | 100 |
|
|
2016
Q4 | $125K | Hold |
1,150
| – | – | 0.02% | 165 |
|
|
2016
Q3 | $147K | Sell |
1,150
-1,268
| -52% | -$132K | 0.02% | 163 |
|
|
2016
Q2 | $220K | Sell |
2,418
-207
| -8% | -$18K | 0.04% | 160 |
|
|
2016
Q1 | $206K | Hold |
2,625
| – | – | 0.03% | 164 |
|
|
2015
Q4 | $292K | Hold |
2,625
| – | – | 0.04% | 167 |
|
|
2015
Q3 | $331K | Buy |
+2,625
| New | +$350K | 0.04% | 174 |
|
Other funds holding CTSO
CM
Skylands Capital's CTSO Position: Q2 2026 in Review
Skylands Capital reduced its Cytosorbents Corp (CTSO) stake by 29% in Q2 2026, selling an estimated $262K and leaving 60,570 shares worth $453K. The position accounts for 0.06% of the portfolio, ranked #125.
Skylands Capital first reported a position in CTSO in Q3 2015 and has held it in 44 quarters since. The position peaked at $14.9M in Q3 2021. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Skylands Capital held 60,570 shares of Cytosorbents Corp worth $453K as of Q2 2026.
- Skylands Capital sold 24,805 Cytosorbents Corp shares in Q2 2026, an estimated $262K.
- Cytosorbents Corp made up 0.06% of Skylands Capital's portfolio in Q2 2026, its #125 holding.
- Skylands Capital first reported a position in Cytosorbents Corp in Q3 2015 and has held it in 44 quarters since.
- Skylands Capital's Cytosorbents Corp position peaked at $14.9M in Q3 2021.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Skylands Capital's 13F filing for Q2 2026, filed 24 Jul 2026.